Close Menu

NEW YORK – Mission Bio said today that it has raised $70 million in a Series C funding round.

The South San Francisco-based firm said it will use the funding to scale its Tapestri singe-cell multi-omics technology, to expand the company's reach in more effective clinical trials for novel cancer treatments, as well as characterization for cell and gene therapy.

Mission Bio's Tapestri platform can simultaneously detect DNA and protein changes from the same cell, which it believes is necessary for developing impactful precision therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.